
|Videos|April 19, 2022
Safety Data on Ruxolitinib in Primary MF
Author(s)Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, comments on safety data from the ruxolitinib clinical trials in patients with MF.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5































